These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 31951127)

  • 1. Discovery of Balovaptan, a Vasopressin 1a Receptor Antagonist for the Treatment of Autism Spectrum Disorder.
    Schnider P; Bissantz C; Bruns A; Dolente C; Goetschi E; Jakob-Roetne R; Künnecke B; Mueggler T; Muster W; Parrott N; Pinard E; Ratni H; Risterucci C; Rogers-Evans M; von Kienlin M; Grundschober C
    J Med Chem; 2020 Feb; 63(4):1511-1525. PubMed ID: 31951127
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase 2 clinical trial of a vasopressin V1a receptor antagonist shows improved adaptive behaviors in men with autism spectrum disorder.
    Bolognani F; Del Valle Rubido M; Squassante L; Wandel C; Derks M; Murtagh L; Sevigny J; Khwaja O; Umbricht D; Fontoura P
    Sci Transl Med; 2019 May; 11(491):. PubMed ID: 31043521
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of balovaptan for socialisation and communication difficulties in autistic adults in North America and Europe: a phase 3, randomised, placebo-controlled trial.
    Jacob S; Veenstra-VanderWeele J; Murphy D; McCracken J; Smith J; Sanders K; Meyenberg C; Wiese T; Deol-Bhullar G; Wandel C; Ashford E; Anagnostou E
    Lancet Psychiatry; 2022 Mar; 9(3):199-210. PubMed ID: 35151410
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Balovaptan vs Placebo for Social Communication in Childhood Autism Spectrum Disorder: A Randomized Clinical Trial.
    Hollander E; Jacob S; Jou R; McNamara N; Sikich L; Tobe R; Smith J; Sanders K; Squassante L; Murtagh L; Gleissl T; Wandel C; Veenstra-VanderWeele J
    JAMA Psychiatry; 2022 Aug; 79(8):760-769. PubMed ID: 35793101
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bioavailability and pharmacokinetic profile of balovaptan, a selective, brain-penetrant vasopressin 1a receptor antagonist, in healthy volunteers.
    Derks M; Lennon-Chrimes S; Guenther A; Squassante L; Wandel C; Szczesny P; Paehler A; Kletzl H
    Expert Opin Investig Drugs; 2021 Aug; 30(8):893-901. PubMed ID: 34176392
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Large multicenter randomized trials in autism: key insights gained from the balovaptan clinical development program.
    Jacob S; Anagnostou E; Hollander E; Jou R; McNamara N; Sikich L; Tobe R; Murphy D; McCracken J; Ashford E; Chatham C; Clinch S; Smith J; Sanders K; Murtagh L; Noeldeke J; Veenstra-VanderWeele J
    Mol Autism; 2022 Jun; 13(1):25. PubMed ID: 35690870
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of highly selective brain-penetrant vasopressin 1a antagonists for the potential treatment of autism via a chemogenomic and scaffold hopping approach.
    Ratni H; Rogers-Evans M; Bissantz C; Grundschober C; Moreau JL; Schuler F; Fischer H; Alvarez Sanchez R; Schnider P
    J Med Chem; 2015 Mar; 58(5):2275-89. PubMed ID: 25654260
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Single Dose, Randomized, Controlled Proof-Of-Mechanism Study of a Novel Vasopressin 1a Receptor Antagonist (RG7713) in High-Functioning Adults with Autism Spectrum Disorder.
    Umbricht D; Del Valle Rubido M; Hollander E; McCracken JT; Shic F; Scahill L; Noeldeke J; Boak L; Khwaja O; Squassante L; Grundschober C; Kletzl H; Fontoura P
    Neuropsychopharmacology; 2017 Aug; 42(9):1914-1923. PubMed ID: 27711048
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New V1a receptor antagonist. Part 1. Synthesis and SAR development of urea derivatives.
    Szántó G; Makó A; Baska F; Bozó É; Domány-Kovács K; Kurkó D; Cselenyák A; Mohácsi R; Kordás KS; Bata I
    Bioorg Med Chem Lett; 2020 Sep; 30(18):127416. PubMed ID: 32736211
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of a triazolobenzodiazepine-based PET probe for subtype-selective vasopressin 1A receptor imaging.
    Haider A; Xiao Z; Xia X; Chen J; Van RS; Kuang S; Zhao C; Rong J; Shao T; Ramesh P; Aravind A; Shao Y; Ran C; Young LJ; Liang SH
    Pharmacol Res; 2021 Nov; 173():105886. PubMed ID: 34536549
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of PF-184563, a potent and selective V1a antagonist for the treatment of dysmenorrhoea. The influence of compound flexibility on microsomal stability.
    Johnson PS; Ryckmans T; Bryans J; Beal DM; Dack KN; Feeder N; Harrison A; Lewis M; Mason HJ; Mills J; Newman J; Pasquinet C; Rawson DJ; Roberts LR; Russell R; Spark D; Stobie A; Underwood TJ; Ward R; Wheeler S
    Bioorg Med Chem Lett; 2011 Oct; 21(19):5684-7. PubMed ID: 21885275
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New V1a receptor antagonist. Part 2. Identification and optimization of triazolobenzazepines.
    Bozó É; Baska F; Lövei K; Szántó G; Domány-Kovács K; Kurkó D; Szondiné Kordás K; Szokoli T; Bata I
    Bioorg Med Chem Lett; 2020 Sep; 30(18):127417. PubMed ID: 32731087
    [TBL] [Abstract][Full Text] [Related]  

  • 13. GABAA receptor subtype-selective modulators. II. α5-selective inverse agonists for cognition enhancement.
    Atack JR
    Curr Top Med Chem; 2011; 11(9):1203-14. PubMed ID: 21050171
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis and pharmacological evaluation of 5-(4-biphenyl)-3-methyl-4-phenyl-1,2,4-triazole derivatives as a novel class of selective antagonists for the human vasopressin V(1A) receptor.
    Kakefuda A; Suzuki T; Tobe T; Tsukada J; Tahara A; Sakamoto S; Tsukamoto S
    J Med Chem; 2002 Jun; 45(12):2589-98. PubMed ID: 12036368
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of New Heterocyclic Ring Systems as Novel and Potent V
    Baska F; Szántó G; Bozó É; Szakács Z; Dékány M; Szondiné Kordás K; Domány-Kovács K; Kurkó D; Hodoscsek B; Magdó I; Krámos B; Béni Z; Vastag M; Bata I
    ACS Chem Neurosci; 2020 Nov; 11(21):3532-3540. PubMed ID: 33084311
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glutamatergic medication in the treatment of obsessive compulsive disorder (OCD) and autism spectrum disorder (ASD) - study protocol for a randomised controlled trial.
    Häge A; Banaschewski T; Buitelaar JK; Dijkhuizen RM; Franke B; Lythgoe DJ; Mechler K; Williams SC; Dittmann RW;
    Trials; 2016 Mar; 17(1):141. PubMed ID: 26983548
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Binding of the non-peptide vasopressin V1a receptor antagonist SR-49059 in the rat brain: an in vitro and in vivo autoradiographic study.
    Tribollet E; Raufaste D; Maffrand J; Serradeil-Le Gal C
    Neuroendocrinology; 1999 Feb; 69(2):113-20. PubMed ID: 9986924
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adaptive behavior in autism: Minimal clinically important differences on the Vineland-II.
    Chatham CH; Taylor KI; Charman T; Liogier D'ardhuy X; Eule E; Fedele A; Hardan AY; Loth E; Murtagh L; Del Valle Rubido M; San Jose Caceres A; Sevigny J; Sikich L; Snyder L; Tillmann JE; Ventola PE; Walton-Bowen KL; Wang PP; Willgoss T; Bolognani F
    Autism Res; 2018 Feb; 11(2):270-283. PubMed ID: 28941213
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preparation of highly potent and selective non-peptide antagonists of the arginine vasopressin V1A receptor by introduction of a 2-ethyl-1H-1-imidazolyl group.
    Shimada Y; Akane H; Taniguchi N; Matsuhisa A; Kawano N; Kikuchi K; Yatsu T; Tahara A; Tomura Y; Kusayama T; Wada K; Tsukada J; Tsunoda T; Tanaka A
    Chem Pharm Bull (Tokyo); 2005 Jul; 53(7):764-9. PubMed ID: 15997131
    [TBL] [Abstract][Full Text] [Related]  

  • 20. N-Methylbenzanilide derivatives as a novel class of selective V(1A) receptor antagonists.
    Kakefuda A; Tsukada J; Kusayama T; Tahara A; Tsukamoto S
    Bioorg Med Chem Lett; 2002 Jan; 12(2):229-32. PubMed ID: 11755361
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.